Geneva, Sept. 21 -- International Clinical Trials Registry received information related to the study (NCT07813026) titled 'Abuse Potential of Gabapentin Taken Orally Concomitantly With Oxycodone Hydrochloride in Healthy, Non-Drug-Dependent, Recreational Opioid Users' on Sept. 4.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Crossover Assignment. Primary purpose: Other. Masking: Double (Participant, Investigator).
Primary Sponsor: Viatris Inc.
Condition:
Healthy, Non-Drug- Dependent, Recreational Opioid Users
Intervention:
Drug: Placebo
Drug: Oxycodone 20mg
Drug: gabapentin 600 mg
Drug: Gabapentin 1200mg
Drug: Gabapentin 600 mg + Oxycodone 20 mg
Recruitment Status: Recruiting
Phase: Phase 4...